We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

58 hedge funds and large institutions have $476M invested in Aimmune Therapeutics in 2015 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 29 increasing their positions, 6 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

383% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 6

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

0% more funds holding

Funds holding: 58 → 58 (0)

0% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 14

14% less capital invested

Capital invested by funds: $551M → $476M (-$75.3M)

Holders
58
Holders Change
–
Holders Change %
0%
% of All Funds
1.52%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.1%
New
14
Increased
29
Reduced
6
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EAM
Eagle Asset Management
Florida
+$15.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.63M
3
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
+$4.48M
4
EA
Emerald Advisers
Pennsylvania
+$4.24M
5
SAM
Sectoral Asset Management
Quebec, Canada
+$3.51M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$25.2M
2
Jennison Associates
Jennison Associates
New York
-$5.08M
3
FAM
Fred Alger Management
New York
-$2.42M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.85M
5
Franklin Resources
Franklin Resources
California
-$1.73M
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
26
ALPS Advisors
Colorado
$1.03M +$1.03M +55,657 New
TCIM
27
TIAA CREF Investment Management
New York
$937K +$318K +17,210 +51%
Federated Hermes
28
Federated Hermes
Pennsylvania
$923K – – –
Bank of New York Mellon
29
Bank of New York Mellon
New York
$822K +$337K +18,206 +69%
BIM
30
BlackRock Investment Management
Delaware
$694K +$9.05K +489 +1%
NI
31
Numeric Investors
Massachusetts
$642K +$644K +34,800 New
Charles Schwab
32
Charles Schwab
California
$485K +$299K +16,185 +161%
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$380K +$5.42K +293 +1%
FAM
34
Fred Alger Management
New York
$318K -$2.42M -131,049 -88%
TA
35
Teachers Advisors
New York
$309K +$101K +5,477 +48%
PPA
36
Parametric Portfolio Associates
Washington
$300K +$301K +16,277 New
Bank of America
37
Bank of America
North Carolina
$287K +$129K +6,959 +81%
TD Asset Management
38
TD Asset Management
Ontario, Canada
$264K +$265K +14,300 New
Swiss National Bank
39
Swiss National Bank
Switzerland
$245K +$246K +13,300 New
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$197K +$198K +10,700 New
MLICM
41
Metropolitan Life Insurance Company (MetLife)
New York
$163K +$163K +8,820 New
NFA
42
Nationwide Fund Advisors
Ohio
$137K +$87K +4,704 +172%
Wells Fargo
43
Wells Fargo
California
$124K +$71.6K +3,868 +136%
PAM
44
Panagora Asset Management
Massachusetts
$118K +$118K +6,375 New
Citigroup
45
Citigroup
New York
$89K +$82.6K +4,466 +1,251%
Morgan Stanley
46
Morgan Stanley
New York
$89K +$83.7K +4,527 +1,509%
BA
47
BlackRock Advisors
Delaware
$68K -$29.7K -1,608 -30%
SO
48
STRS Ohio
Ohio
$66K – – –
Deutsche Bank
49
Deutsche Bank
Germany
$50K -$5.55K -300 -10%
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$42.1K +$4.01K +217 +11%
1
2
3

AIMT Hedge Fund Activity: Q4 2015 in Review

58 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q4 2015, worth a combined $476M — down 14% from $551M a quarter earlier.

Fund positioning in AIMT was balanced in Q4 2015: 14 funds opened new positions, 14 closed out, 29 added to existing stakes and 6 trimmed.

The largest buyer was Eagle Asset Management, opening a new position worth an estimated $15.8M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $25.2M sold.

  • 58 institutional investors held Aimmune Therapeutics (AIMT) as of Q4 2015, unchanged from Q3 2015.
  • Funds reported $476M of Aimmune Therapeutics stock for Q4 2015, down 14% quarter-over-quarter.
  • 14 funds opened new Aimmune Therapeutics positions in Q4 2015 and 14 closed out, a net change of 0 holders.
  • The largest Aimmune Therapeutics buyer in Q4 2015 was Eagle Asset Management, an estimated $15.8M added.
  • The largest Aimmune Therapeutics seller in Q4 2015 was PFM Health Sciences, an estimated $25.2M sold.

Based on aggregated 13F filings for Q4 2015.